Susan Moench, PhD, PA-C

A meta-analysis sought to determine if survival is improved with dual targeting of the MAPK pathway with BRAF and MEK inhibitors vs BRAF inhibition alone in patients with advanced melanoma.

Although extreme thrombocytosis occurs rarely, researchers were able to identify its underlying cause and potential prognosis for patients who develop the condition.

Researchers sought to determine whether late mortality rates are affected by exposure to a BCR-ABL TKI prior to BMT in patients with CML who survive at least 2 years posttransplantation.

An expanded treatment protocol study sought to validate the safety and efficacy of ruxolitinib, a JAK kinase inhibitor approved by the FDA for the treatment of polycythemia vera in patients who are intolerant of, or resistant to, hydroxyurea.

The results of a retrospective study published in Resuscitation suggest that post-resuscitation interventions are less aggressive following in-hospital cardiac arrest for patients with cancer compared with individuals without a history of cancer. Although there is evidence that the clinical outcomes of patients experiencing in-hospital cardiac arrest, as well as of patients with cancer in general,…

Two randomized phase 3 trials investigating the safety and efficacy of adding pembrolizumab to standard-of-care therapies for multiple myeloma were halted due to poor outcomes in their respective intervention arms.

Key factors that influence choice of TKI for frontline treatment of chronic-phase CML are reviewed, as well as the role for pharmacists in the multidisciplinary oncology care team.

Retrospective population-based cohort study is used to validate a new risk assessment tool to identify patients receiving immunomodulatory drugs for multiple myeloma who may be at high risk of VTE.

An expert panel convened by MASCC/ISOO and ASCO updated the clinical practice guidelines for prevention and management of medication-related osteonecrosis of the jaw.